- Global Pharma News & Resources

Press Releases - 2022-12-14

Date Title Company
14-Dec-2022 Targeted Timing of Palliative Care for Lung Cancer KL Krems
14-Dec-2022 Biologic API CDMO Benchmarking for New & Emerging Biopharma: Increased Investment and Presence of Start-Ups Galvanizes Sector - Businesswire
14-Dec-2022 Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Twist Bioscience Corporation (TWST) Businesswire
14-Dec-2022 Plasma-Derived Drugs Market is expected to reach a valuation of US$ 74 Bn by 2032 MARKITWIRED
14-Dec-2022 Soft Tissue Release Systems Market Growth, Regional Analysis, Trends and Forecast 2022-2032 MARKITWIRED
14-Dec-2022 CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program CureVac
14-Dec-2022 UK Patient's Perspective on the Corporate Reputation of Pharma, 2021-2022: Pfizer Ranked 1st, Roche Ranked 2nd, AstraZeneca Ranked 3rd - Businesswire
14-Dec-2022 Medical Grade Tubing Global Market Report 2022: Increasing Prevalence of Diseases to Drive Growth - Businesswire
14-Dec-2022 Masterbatch Global Market Report 2022: Increasing Demand for Biodegradable Masterbatches to Foster Growth - Businesswire
14-Dec-2022 The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups - Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd - Businesswire
14-Dec-2022 Global Quantum Computing Market Report 2022: Increasing Investment in Development and Deployment Fuels Growth - Businesswire
14-Dec-2022 Oncology Biosimilars Global Market Report 2022: Robust Pipeline of Monoclonal Antibodies to Drive Growth - Businesswire
14-Dec-2022 Global Cell Therapy Technologies Market to Reach $12.27 Billion by 2030 at a 14.5% CAGR - Businesswire
14-Dec-2022  Takeda adquire o melhor inibidor em potencial de TYK2 oral e alostérico de sua categoria: NDI-034858 da Nimbus Therapeutics Businesswire
14-Dec-2022 Takeda erwirbt den oralen allosterischen TYK2-Inhibitor NDI-034858 von Nimbus Therapeutics, der sich in einem fortgeschrittenen Stadium befindet und „Best in Class“-Potenzial aufweist Businesswire
14-Dec-2022 Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture  SAE Media Group
14-Dec-2022 Smart Container Global Market Report 2022: Increased Demand from Commercial and Residential Sectors to Boost Growth - Businesswire
14-Dec-2022 Genome Engineering Global Market Report 2022: Increasing Development of Novel Technologies Drives Growth - Businesswire
14-Dec-2022 Takeda adquiere NDI-034858 a Nimbus Therapeutics, un fármaco en la última fase de desarrollo que podría convertirse en el mejor inhibidor oral alostérico de TYK2 Businesswire
14-Dec-2022 Douglas GmbH: Release of results for the 4th quarter and full year 2021/22 (ending 30 September 2022) on 20 December 2022 Douglas GmbH